Roger Hofseth has, in his capacity as chairman of the board of directors, received proxies to vote for 46,838,168 shares in Hofseth BioCare ASA (the "Company"), corresponding to 20.06 % of the total outstanding shares and votes at the Company's extraordinary general meeting to be held at 24 March 2017. The proxies received are only valid for the general meeting and will lapse thereafter.

 

Roger Hofseth, through his wholly owned company Roger Hofseth AS, owns 37,217,701 shares in the Company and may, together with the received proxies, vote for 84,055,869 shares, corresponding to 36.01 % of the votes.

 

For further information, please contact:

Tor Erik Andersen, CEO of Hofseth BioCare ASA
Mob: +47 911 79 854
E-mail: tea@hofsethbiocare.no

 

Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

 

About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

 

Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

 

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.